18F-FDG PET/CT Brain Imaging

FDG PETCT in colorectal cancer

Colorectal cancer represents the second most common malignancy worldwide, with approximately one million newly diagnosed cases each year, and is the fourth leading cause of cancer mortality. This article provides an overview of the role of FDG (fluorodeoxyglucose) PET (positron emission tomography) CT (computed tomography) for assessment in patients with colorectal cancer. A summary of key lear...

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

UNLABELLED 3'-Deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) is a recently developed PET tracer to image tumor cell proliferation. We characterized (18)F-FLT PET of brain gliomas and compared (18)F-FLT with (18)F-FDG PET in side-by-side studies of the same patients. METHODS Twenty-five patients with newly diagnosed or previously treated glioma underwent PET with (18)F-FLT and (18)F-FDG on consecu...

A Dual Tracer 18F-FCH/18F-FDG PET Imaging of an Orthotopic Brain Tumor Xenograft Model

Early diagnosis of low grade glioma has been a challenge to clinicians. Positron Emission Tomography (PET) using 18F-FDG as a radio-tracer has limited utility in this area because of the high background in normal brain tissue. Other radiotracers such as 18F-Fluorocholine (18F-FCH) could provide better contrast between tumor and normal brain tissue but with high incidence of false positives. In ...

18F-FDG imaging: pitfalls and artifacts.

18F-FDG PET is emerging as a useful tool in the staging and restaging of many malignant neoplasms, such as lymphoma, lung cancer, colorectal cancer, head and neck cancer, breast cancer, and melanoma. To accurately interpret 18F-FDG findings one must be familiar with the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of 18...

Reduced-dose [F]-FDG PETCT scanning with current generation PETCT systems